Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chohee Yun

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The Lancet. Gastroenterology & Hepatology|April 12, 2017
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trialJürgen K Rockstroh, Sanjay Bhagani, Robert H Hyland, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2016
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION TrialsJason Grebely, Stefan Mauss, Ashley Brown, et al.
Annals of Internal Medicine|November 15, 2016
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized TrialMassimo Colombo, Alessio Aghemo, Hong Liu, et al.
Plos One|March 20, 2012
TRAF6 mediates IL-1β/LPS-induced suppression of TGF-β signaling through its interaction with the type III TGF-β receptorSeunghwan Lim, Eunjin Bae, Hae-Suk Kim, et al.
Intestinal Research|March 10, 2022
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trialToshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, et al.
The American Journal of Gastroenterology|September 16, 2022
Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION TrialSilvio Danese, Marc Ferrante, Brian G Feagan, et al.
Journal of Hepatology|January 22, 2017
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcomeStefan Zeuzem, Masashi Mizokami, Stephen Pianko, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2017
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label StudyJordan J Feld, Alnoor Ramji, Stephen D Shafran, et al.
Lancet (London, England)|June 6, 2021
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trialBrian G Feagan, Silvio Danese, Edward V Loftus, et al.
Gastroenterology|November 28, 2017
Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBVChun-Jen Liu, Wan-Long Chuang, I-Shyan Sheen, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Lancet. Gastroenterology & Hepatology|April 12, 2017
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trialJürgen K Rockstroh, Sanjay Bhagani, Robert H Hyland, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2016
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION TrialsJason Grebely, Stefan Mauss, Ashley Brown, et al.
Annals of Internal Medicine|November 15, 2016
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized TrialMassimo Colombo, Alessio Aghemo, Hong Liu, et al.
Plos One|March 20, 2012
TRAF6 mediates IL-1β/LPS-induced suppression of TGF-β signaling through its interaction with the type III TGF-β receptorSeunghwan Lim, Eunjin Bae, Hae-Suk Kim, et al.
Intestinal Research|March 10, 2022
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trialToshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, et al.
The American Journal of Gastroenterology|September 16, 2022
Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION TrialSilvio Danese, Marc Ferrante, Brian G Feagan, et al.
Journal of Hepatology|January 22, 2017
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcomeStefan Zeuzem, Masashi Mizokami, Stephen Pianko, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2017
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label StudyJordan J Feld, Alnoor Ramji, Stephen D Shafran, et al.
Lancet (London, England)|June 6, 2021
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trialBrian G Feagan, Silvio Danese, Edward V Loftus, et al.
Gastroenterology|November 28, 2017
Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBVChun-Jen Liu, Wan-Long Chuang, I-Shyan Sheen, et al.
Pageof 2